Literature DB >> 15680148

Cost efficient and effective gene transfer into the human natural killer cell line, NK92.

Eric M Grund1, Robin C Muise-Helmericks.   

Abstract

Introducing genes into cells is a crucial step in many fields of basic research, as well as for the development of new drugs and therapies. Many cell types are resistant to normal methods of gene delivery, such as lipid based transfection and electroporation. Delivery to resistant cell lines can be costly or inefficient. Natural killer (NK) cells are highly resistant to transfection. We have developed a novel method to deliver exogenous genes in the NK cell line, NK92. Using a combination of electroporation and a defined buffer, we were able to obtain an electroporation efficiency of 40% in NK92 cells. Using RNAi, we show significant reduction of an endogenous protein (ETS1) using this optimized buffer and electroporation conditions. Taken together, the results show a functional and cost effective method for the expression of exogenous genes in NK cells.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15680148     DOI: 10.1016/j.jim.2004.10.008

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  8 in total

1.  Inhibition of intracellular antiviral defense mechanisms augments lentiviral transduction of human natural killer cells: implications for gene therapy.

Authors:  Tolga Sutlu; Sanna Nyström; Mari Gilljam; Birgitta Stellan; Steven E Applequist; Evren Alici
Journal:  Hum Gene Ther       Date:  2012-09-10       Impact factor: 5.695

2.  Surviving high-intensity field pulses: strategies for improving robustness and performance of electrotransfection and electrofusion.

Authors:  V L Sukhorukov; R Reuss; D Zimmermann; C Held; K J Müller; M Kiesel; P Gessner; A Steinbach; W A Schenk; E Bamberg; U Zimmermann
Journal:  J Membr Biol       Date:  2005-08       Impact factor: 1.843

Review 3.  Genetic Manipulation of NK Cells for Cancer Immunotherapy: Techniques and Clinical Implications.

Authors:  Mattias Carlsten; Richard W Childs
Journal:  Front Immunol       Date:  2015-06-10       Impact factor: 7.561

Review 4.  CAR-engineered NK cells; a promising therapeutic option for treatment of hematological malignancies.

Authors:  Faroogh Marofi; Marwan Mahmood Saleh; Heshu Sulaiman Rahman; Wanich Suksatan; Moaed E Al-Gazally; Walid Kamal Abdelbasset; Lakshmi Thangavelu; Alexei Valerievich Yumashev; Ali Hassanzadeh; Mahboubeh Yazdanifar; Roza Motavalli; Yashwant Pathak; Adel Naimi; Behzad Baradaran; Marzieh Nikoo; Farhad Motavalli Khiavi
Journal:  Stem Cell Res Ther       Date:  2021-07-02       Impact factor: 6.832

Review 5.  CAR-NK Cell: A New Paradigm in Tumor Immunotherapy.

Authors:  Faroogh Marofi; Alaa S Al-Awad; Heshu Sulaiman Rahman; Alexander Markov; Walid Kamal Abdelbasset; Yulianna Ivanovna Enina; Mahnaz Mahmoodi; Ali Hassanzadeh; Mahboubeh Yazdanifar; Max Stanley Chartrand; Mostafa Jarahian
Journal:  Front Oncol       Date:  2021-06-10       Impact factor: 6.244

6.  An efficient low cost method for gene transfer to T lymphocytes.

Authors:  Leonardo Chicaybam; Andressa Laino Sodre; Bianca Azevedo Curzio; Martin Hernan Bonamino
Journal:  PLoS One       Date:  2013-03-26       Impact factor: 3.240

7.  Resveratrol induces cell cycle arrest and apoptosis in malignant NK cells via JAK2/STAT3 pathway inhibition.

Authors:  Ly Quoc Trung; J Luis Espinoza; Akiyoshi Takami; Shinji Nakao
Journal:  PLoS One       Date:  2013-01-25       Impact factor: 3.240

Review 8.  NK Cells Armed with Chimeric Antigen Receptors (CAR): Roadblocks to Successful Development.

Authors:  Ali Bashiri Dezfouli; Mina Yazdi; Alan Graham Pockley; Mohammad Khosravi; Sebastian Kobold; Ernst Wagner; Gabriele Multhoff
Journal:  Cells       Date:  2021-12-01       Impact factor: 6.600

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.